WOOJUNG BIO Inc Net Assets
WOOJUNG BIO Inc net assets. Based on the latest financial reports, WOOJUNG BIO Inc (215380) has net assets worth ₩26.58 Billion KRW (≈ $18.01 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩103.30 Billion ≈ $70.00 Million USD) and total liabilities (₩76.72 Billion ≈ $51.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 215380 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩26.58 Billion |
| % of Total Assets | 25.73% |
| Annual Growth Rate | 9.22% |
| 5-Year Change | -25.69% |
| 10-Year Change | N/A |
| Growth Volatility | 28.47 |
Net Assets of WOOJUNG BIO Inc (2016–2025)
Net assets of WOOJUNG BIO Inc from 2016 to 2025. This chart illustrates how WOOJUNG BIO Inc's net assets have evolved over time, based on quarterly financial data. See 215380 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for WOOJUNG BIO Inc (2016–2025)
The table below shows the annual net assets of WOOJUNG BIO Inc from 2016 to 2025. For live market cap and overall valuation, see 215380 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩23.38 Billion ≈ $15.84 Million |
-20.41% |
| 2024-12-31 | ₩29.37 Billion ≈ $19.91 Million |
+33.68% |
| 2023-12-31 | ₩21.97 Billion ≈ $14.89 Million |
-26.07% |
| 2022-12-31 | ₩29.72 Billion ≈ $20.14 Million |
-5.54% |
| 2021-12-31 | ₩31.46 Billion ≈ $21.32 Million |
+12.23% |
| 2020-12-31 | ₩28.03 Billion ≈ $19.00 Million |
+5.14% |
| 2019-12-31 | ₩26.66 Billion ≈ $18.07 Million |
+25.77% |
| 2018-12-31 | ₩21.20 Billion ≈ $14.37 Million |
+15.68% |
| 2017-12-31 | ₩18.32 Billion ≈ $12.42 Million |
+73.41% |
| 2016-12-31 | ₩10.57 Billion ≈ $7.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to WOOJUNG BIO Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23117.6% over the analyzed period, potentially due to dividend distributions or operating losses.
WOOJUNG BIO Inc Net Assets Breakdown (December 2025)
WOOJUNG BIO Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩54.43 Billion | 232.84% |
| Total Equity | ₩23.38 Billion | 100.00% |
WOOJUNG BIO Inc Competitors by Market Cap
The table below lists competitors of WOOJUNG BIO Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nextplat Corp
NASDAQ:NXPL
|
$21.84 Million |
|
Kidoz Inc
V:KIDZ
|
$21.85 Million |
|
Slj Global Tbk
JK:SULI
|
$21.85 Million |
|
Filter Vision Public Company Limited
BK:FVC
|
$21.85 Million |
|
Tekom Technologies
TWO:6294
|
$21.83 Million |
|
First Graphene Ltd
F:M11
|
$21.83 Million |
|
Quickfee Ltd
AU:QFE
|
$21.82 Million |
|
Leviathan Gold Ltd
V:LVX
|
$21.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in WOOJUNG BIO Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,372,956,890 to 23,377,942,350, a change of -5,995,014,540 (-20.4%).
- Net loss of 5,546,594,980 reduced equity.
- Other factors decreased equity by 448,419,560.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.55 Billion | -23.73% |
| Other Changes | ₩-448.42 Million | -1.92% |
| Total Change | ₩- | -20.41% |
Book Value vs Market Value Analysis
This analysis compares WOOJUNG BIO Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.40x to 1.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4803.34 | ₩1933.00 | x |
| 2017-12-31 | ₩2129.55 | ₩1933.00 | x |
| 2018-12-31 | ₩2179.11 | ₩1933.00 | x |
| 2019-12-31 | ₩2550.17 | ₩1933.00 | x |
| 2020-12-31 | ₩2348.89 | ₩1933.00 | x |
| 2021-12-31 | ₩2474.51 | ₩1933.00 | x |
| 2022-12-31 | ₩2322.02 | ₩1933.00 | x |
| 2023-12-31 | ₩1479.97 | ₩1933.00 | x |
| 2024-12-31 | ₩1761.97 | ₩1933.00 | x |
| 2025-12-31 | ₩1402.35 | ₩1933.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently WOOJUNG BIO Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.76%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 3.71x
- Recent ROE (-23.73%) is below the historical average (-15.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.73% | 0.36% | 1.79x | 1.14x | ₩-979.49 Million |
| 2017 | -37.77% | -23.92% | 0.92x | 1.71x | ₩-8.75 Billion |
| 2018 | -18.76% | -16.74% | 0.53x | 2.11x | ₩-6.10 Billion |
| 2019 | 1.05% | 0.87% | 0.56x | 2.16x | ₩-2.39 Billion |
| 2020 | -38.81% | -29.13% | 0.53x | 2.49x | ₩-13.68 Billion |
| 2021 | -6.12% | -6.16% | 0.31x | 3.18x | ₩-5.07 Billion |
| 2022 | -6.33% | -4.01% | 0.49x | 3.20x | ₩-4.85 Billion |
| 2023 | -23.00% | -13.09% | 0.39x | 4.48x | ₩-7.25 Billion |
| 2024 | 0.77% | 0.52% | 0.46x | 3.22x | ₩-2.71 Billion |
| 2025 | -23.73% | -14.76% | 0.43x | 3.71x | ₩-7.88 Billion |
Industry Comparison
This section compares WOOJUNG BIO Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $417,529,273,243
- Average return on equity (ROE) among peers: -6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| WOOJUNG BIO Inc (215380) | ₩26.58 Billion | 0.73% | 2.89x | $21.84 Million |
| ORIENTBIO Inc. (002630) | $97.94 Billion | -19.53% | 0.76x | $96.19 Million |
| Green Cross (005250) | $1.97 Trillion | 1.67% | 0.83x | $290.81 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $367.60 Million |
| GeneOne Life Science Inc (011000) | $111.49 Billion | -69.75% | 0.35x | $32.81 Million |
| HLB Co. Ltd (028300) | $88.75 Billion | -14.89% | 1.10x | $3.02 Billion |
| Mgenplus Co. Ltd. (032790) | $18.79 Billion | 0.00% | 1.65x | $19.98 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $21.44 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $356.42 Million |
About WOOJUNG BIO Inc
Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and e… Read more